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Introduction
Chromosomal translocations are the most common class of 
mutations found in hematological malignancies (Küppers, 2005). 
In addition, recurrent chromosomal fusions have been causally 
implicated in sarcomas and other solid tumors (Kumar-Sinha 
et al., 2008). There are a few common mechanisms by which 
translocations provide a proliferative or survival advantage to 
an incipient cancer cell. First, when cis-regulatory transcrip-
tional elements from one gene are apposed to a proto-onco-
gene, this causes aberrant expression of the growth-promoting 
oncogene. For example, Burkitt’s lymphoma carries a recip-
rocal translocation that results in fusion of the coding region 
of the c-myc proto-oncogene with the immunoglobulin heavy 
chain (IgH) (Jankovic et al., 2007), which places c-myc under 
the control of the 3′ regulatory elements of IgH (Gostissa et 
al., 2009). c-myc is thereby deregulated and promotes cellular 
transformation through its effects on the cell cycle, differentia-
tion, and apoptosis. A second mechanism by which transloca-
tions may promote transformation involves the fusion of two 
genes to produce a chimeric protein with oncogenic activity. 
A prototypical example is the Philadelphia chromosome found 
in a subtype of acute lymphoblastic leukemia (Ph+ ALL) and 
chronic myeloid leukemia (CML), in which the BCR-ABL fusion 
gene encodes a protein with deregulated kinase activity. BCR-
ABL expression results in cytokine-independent growth, resis-
tance to apoptosis, and genetic instability (Küppers, 2005). 
In addition to protein encoding genes, chromosomal translo-
cations can also involve microRNA genes (Calin et al., 2004). 
Structural and functional alterations in these small noncoding 
RNAs have been detected in various cancers and may play a 
causal role in tumorigenesis (Calin and Croce, 2007; Robbiani 
et al., 2009).
Translocation requires (1) formation of paired double strand 
DNA breaks (DSBs) on separate chromosomes, (2) proximity 
of broken ends (at least transiently), and (3) joining of the het-
erologous DNA ends, as opposed to fusion in cis (Figure 1). 
Although many different cancers carry recurrent chromosome 
translocations (see http://www.sanger.ac.uk/genetics/CGP/
Census/translocation.shtml), this review will focus on the etiol-
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abnormalities found in cancer cells. Oncogenic chromosomal translocations provide cells with a 
proliferative or survival advantage. They may either initiate transformation or be acquired secondarily 
as a result of genomic instability. Here, we highlight recent advances toward understanding the origin 
of chromosomal translocations in incipient lymphoid cancers and how tumor-suppressive pathways 
normally limit the frequency of these aberrant recombination events. Deciphering the mechanisms 
that mediate chromosomal fusions will open new avenues for developing therapeutic strategies 
aimed at eliminating lesions that lead to the initiation, maintenance, and progression of cancer.
Figure 1. Misrepair of DNA Breaks Cause Chromosomal 
 Translocations
Chromosomal translocations require formation of paired double-strand DNA 
breaks (DSBs) on different chromosomes. DSBs can be repaired in cis or can 
result in chromosomal translocation by rearrangement between nonhomolo-
gous chromosomes. Depending on the topology of the rearrangement, the 
translocation can be reciprocal (balanced or unbalanced) or nonreciprocal. 
The majority of translocations associated with cancer in human lymphoid tu-
mors involve balanced chromosomal translocations, whereas epithelial can-
cers usually carry complex nonreciprocal translocations.
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ogy of translocations in lymphocytes as these are the most well 
characterized to date. We expect that most incipient cancer 
cells will share the basic mechanisms involved in the develop-
ment of and protection against chromosomal translocations.
Chromosomal Translocations in Context
Approximately 95% of all lymphomas are of B cell origin (Küp-
pers, 2005). These cancers are heterogeneous, involving all B 
cell developmental stages: from early B cells in acute lympho-
blastic leukemia (ALL) to mature B cells in Burkitt’s lymphoma 
and plasma cells in multiple myeloma. Despite their disparate 
origins, many of these cancers carry balanced chromosomal 
translocations that involve immunoglobulin (Ig) genes and 
oncogenic partner genes (Figure 1); in rarer cases, transloca-
tions can be nonreciprocal or join two non-Ig genes (Küppers, 
2005).
Why are B cells particularly susceptible to transformation by 
chromosome translocation? This issue has been the subject 
of much debate, beginning immediately after these abnormal 
cytological features were discovered. A great deal of the dis-
cussion has focused on antigen receptor gene diversification 
during V(D)J recombination, somatic hypermutation (SHM) 
and class switch recombination (CSR), as all three require 
programmed DNA damage (Figure 2). The notion that anti-
body gene diversification reactions initiate translocations was 
strongly bolstered when the first lymphoid cancer associated 
translocation was characterized as a fusion between c-myc 
and the switch region of the IgH locus, suggesting that c-myc/
IgH translocations arise as a byproduct of aberrant Ig class 
switching (Jankovic et al., 2007). In the ensuing years, many 
additional translocations have been documented in lymphoid 
cancers, and in most though not all cases, at least one of the 
partner chromosomes was an Ig variable or switch region. 
Translocations involving two non-Ig genes are interesting 
exceptions to the rule; however, this group of translocations 
may also be products of “off target” genome destabilization 
by the Ig V(D)J recombinase, recombinase-activating gene 1/2 
(RAG1/2), and/or activation induced cytidine deaminase (AID) 
(Robbiani et al., 2009; Tsai et al., 2008) (see below).
Although less is known about translocations in other cell 
types, they appear to be frequent events in solid tumors, espe-
cially in sarcomas and prostate cancer (Lin et al., 2009; Mitel-
man et al., 2007; Tomlins et al., 2007). Recently published work 
suggests that in prostate cells interchromosomal interactions 
Figure 2. Antigen Diversification Reactions in Lymphocytes
Lymphocyte antigen receptor diversity is established in developing lymphocytes by V(D)J recombination. Recombinase-activating genes 1 and 2 (RAG1 and 
RAG2) are transesterases that introduce double-strand breaks (DSBs) at recombination signal sequences (shown in triangles) that flank V, D, and J gene seg-
ments. These DSBs are repaired by the NHEJ pathway. Mature B cells undergo two additional diversification reactions called somatic hypermutation and 
class-switch recombination. These two processes are initiated by AID, a single-strand DNA deaminase that mutates cytidine residues to uracyl. Cytdine deami-
nation at V regions leads to somatic mutation whereas the same alteration in switch (S) regions causes class switching. AID generated mismatches in DNA are 
processed by base-exision repair (BER), mismatch repair (MMR), and error prone polymerases to generate mutations during somatic hypermutation. These 
lesions can also be converted to a DSB, an obligate intermediate during class-switch recombination. These DSBs are detected and processed by foci-forming 
factors, nonhomologous end joining (NHEJ), and alternative end joining (A-NHEJ). Accurate repair of DSBs by foci-forming factors and NHEJ is necessary to 
prevent chromosomal translocation. Most lymphoid cancers carry chromosomal translocations that involve RAG1/2 or AID target genes. Eµ, intronic enhancer; 
3′E, 3′ enhancer.
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and translocations are induced by transcription factors and 
possibly by aberrant expression of AID (Lin et al., 2009). Andro-
gen receptors are thought to juxtapose translocating loci and 
recruit enzymatic activities such as AID or ORF2 endonuclease 
that produce DSBs (Lin et al., 2009).
DSBs Associated with Antigen Receptor Diversification
V(D)J Recombination
V(D)J recombination is a site-specific DNA remodeling reaction 
required for the assembly of antigen receptor genes in devel-
oping B and T lymphocytes (Figure 2). This reaction is medi-
ated by the RAG1/2 recombinase, which nicks DNA at recom-
bination signal sequences and catalyzes a trans-esterification 
reaction, leading to the formation of paired hairpin (coding end) 
and blunt (signal end) DNA ends. These breaks can trigger the 
DNA damage response (Chen et al., 2000) and are resolved 
by the nonhomologous end-joining (NHEJ) DNA repair machin-
ery, whose components include the Ku70/Ku80 heterodimer, 
DNA-dependent protein kinase catalytic subunit (DNA-PKcs), 
Artemis, XLF/Cernunnos, XRCC4, and DNA Ligase IV (Lig4) (de 
Villartay, 2009; Sleckman, 2005) (Figure 3). To date, Artemis 
and DNA-PKcs have been implicated in hairpin opening and 
are not required for the resolution of signal ends, whereas the 
other NHEJ components are essential for joining both coding 
and signal ends.
RAG1/2 can also function as a transposase in vitro (Jones 
and Gellert, 2004; Schatz and Spanopoulou, 2005). The trans-
posase activity has been proposed as a means by which 
this enzyme can produce translocations; however, exten-
sive sequence analysis indicates that this event is unlikely to 
occur frequently. Instead, the V(D)J-associated translocations 
appear to be the result of aberrant joining of unresolved coding 
ends, as indicated by their proximity to translocation junctions 
in t(11;14) bcl-1/IgH translocations in mantle cell lymphoma and 
t(14;18) bcl-2/IgH translocations in follicular lymphoma and in 
primary mouse T cells (Curry et al., 2007; Küppers, 2005).
In addition to creating breaks in genes that contain recombina-
tion signal sequences, RAG1/2 is thought to be able to produce 
breaks in oncogenes, such as bcl-2, that contain non-B-DNA or 
methyl-CpGs (Raghavan et al., 2004; Tsai et al., 2008). Although 
there is as yet no direct evidence that RAG1/2 can cleave these 
genes in B lymphocytes, cleavage activity on non-B-DNA lack-
ing a recombination signal sequence (RSS) has been detected 
in transfected cell lines with purified substrates in vitro (Ragha-
van et al., 2004). In addition, the RAG1/2 recombinase is also 
capable of acting as a nuclease and nicking mismatches and 
processing nicks, gaps, and flaps into DSBs (Santagata et al., 
1999). Thus, RAG1/2 creates DSBs in Ig genes and has the abil-
ity to produce lesions in other genes as well.
RAG-Induced Translocations and Cancer in Mice
Direct evidence that RAG1/2 activity mediates chromosome 
translocations in vivo comes from analyses of mice deficient 
in NHEJ proteins (Jankovic et al., 2007). NHEJ-deficient mice 
are unable to complete V(D)J recombination, and therefore 
developing lymphocytes in these mice carry unresolved DNA 
breaks. However, developing NHEJ-deficient lymphocytes 
do not usually harbor translocations, and mutant mice do not 
rapidly develop cancer. This is thought to be due to the fact 
that unresolved V(D)J breaks normally trigger p53 dependent 
apoptosis (Guidos et al., 1996). Consistent with this notion, 
mice deficient in both NHEJ and p53 invariably develop pro-
genitor B cell lymphoma at an early age; in the majority of 
cases, these tumors harbor clonal nonreciprocal translocations 
between IgH and c-myc, and both genes are commonly ampli-
fied. Importantly, these DNA rearrangements require RAG1/2-
induced DNA cleavage (Difilippantonio et al., 2002; Zhu et al., 
2002). The majority of breakpoints in the IgH locus are near 
the JH cluster, which further supports the role of failed V(D)J 
recombination in translocation. The breakpoints on Chr15 are 
localized 70–700 kb from the 3′ end of c-myc (Difilippantonio 
et al., 2002; Zhu et al., 2002). This is distinct from what occurs 
in human Burkitt’s lymphoma, where translocations between 
IgH and c-myc are usually reciprocal (meaning that there is 
equal exchange between both broken chromosomes) and IgH 
sequences are usually joined to a sequence cluster near exon 1 
of c-myc. Thus, although the RAG1/2 endonuclease catalyzes 
IgH breaks, the mechanism for c-myc breakage in NHEJ-defi-
cient tumors remains unclear, as are the DNA repair pathways 
that catalyze these complex oncogenic fusion and amplifica-
tion events in the absence of NHEJ. In addition to showing 
that aberrant end-joining pathways can lead to translocations, 
these studies also make it clear that p53 activation protects 
against RAG-mediated translocations.
Figure 3. Repair of DNA Double-Strand Breaks
Two major mechanisms that repair double-strand breaks (DSBs) include ho-
mologous recombination (HR) and nonhomologous end joining (NHEJ). HR 
repairs DSBs by using an intact copy of the broken chromosome as template 
and is restricted in S and G2 phases of the cell cycle. HR is initiated by 5′-3′ 
resection of DSBs to form single-stranded DNA. A complex of BRCA1, MRN, 
and CtIP is required for DSB resection. After ssDNA generation, a RAD51 
nucleoprotein filament facilitated by BRCA2 is formed that initiates strand in-
vasion of the intact sister chromatid. After DNA synthesis, the ends are even-
tually rejoined to yield the intact products. During NHEJ, DNA ends are recog-
nized by the Ku70/80 heterodimer and DNA-PKcs. They are then processed 
by a complex consisting of Artemeis, XLF, XRCC4, and Lig4. Alternative NHEJ 
(A-NHEJ) pathways may also function as a backup to classical NHEJ. NHEJ 
and HR components are caretakers that maintain genomic stability by sup-
pressing chromosomal translocations.
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Somatic Hypermutation and Class Switching
Somatic hypermutation introduces nontemplated nucleotide 
substitutions into the variable region of Ig genes in mature 
B cells that have been stimulated during immune responses 
(Di Noia and Neuberger, 2007; Peled et al., 2008) (Figure 
2). Antibody variants with higher affinity for the antigen are 
selected during the germinal center response, leading to an 
overall increase in antibody affinity (Meffre et al., 2000). CSR 
is a region-specific deletional recombination reaction that 
replaces one antibody constant region for another while main-
taining the specificity of the antibody (Stavnezer et al., 2008) 
(Figure 2). Switched antibody variants have unique effector 
functions; for example, IgA is specialized for secretion into 
milk. Nearly a decade ago, groups led by Tasuku Honjo and 
Anne Durandy discovered that activation-induced cytidine 
deaminase (AID) is essential for both CSR and SHM in mice 
and humans (Muramatsu et al., 2000; Revy et al., 2000) (Fig-
ure 2). Shortly thereafter, nuclear foci of γ-H2AX and Nbs1, 
which mark sites of DNA damage, were found to accumu-
late specifically at the IgH locus in an AID-dependent manner 
(Petersen et al., 2001); this led to the conclusion that AID acts 
upstream of DSB formation during CSR and that the canoni-
cal cellular DNA damage response is involved in the process-
ing of AID-induced DSBs (Petersen et al., 2001). In addition, 
AID-dependent damage foci formed in G0/G1, indicating that 
like RAG1/2-induced DSBs, AID-dependent DSBs may be 
restricted to this phase of the cell cycle. These cytological 
observations were later confirmed by ligation-mediated poly-
merase chain reaction (PCR) assays (Schrader et al., 2007) 
and by studies showing that DNA repair mutants undergo-
ing CSR accumulate IgH-specific chromosome breaks (rather 
than S phase-generated chromatid breaks) in mitotic spreads 
(Franco et al., 2006; Ramiro et al., 2006).
Although these studies did not pinpoint the mechanism by 
which AID functions during gene rearrangements or trans-
location, pioneering work by Michael Neuberger and col-
leagues supported a unifying model in which AID promotes 
both class switching and somatic hypermutation (Di Noia and 
Neuberger, 2007; Peled et al., 2008). According to this model, 
AID acts by deaminating cytosine residues in single-strand 
DNA (ssDNA) that is exposed during transcription. The result-
ing uracil:guanine mismatches are then recognized by the 
uracil DNA glycosylase or the mismatch repair proteins and 
processed in an error-prone manner by DNA repair pathways 
leading either to mutation or DSBs, which are intermediates 
in class switching (Di Noia and Neuberger, 2007; Stavnezer 
et al., 2008). This model is consistent with a profound defect 
in class switching in knockout mice lacking uracil DNA gly-
cosylase and hyper IgM syndrome in humans deficient for 
uracil DNA glycosylase (Imai et al., 2003; Rada et al., 2002). 
Furthermore, it is in agreement with the defects in SHM and 
CSR found in Msh2/6 mutant mice (Di Noia and Neuberger, 
2007; Peled et al., 2008; Stavnezer et al., 2008). Finally, this 
model is also supported by direct biochemical and genetic 
experiments showing that cytosine residues in ssDNA, which 
are exposed during transcription, are the preferred substrate 
for AID (Di Noia and Neuberger, 2007; Peled et al., 2008; 
Stavnezer et al., 2008).
AID Mutations in Non-Ig Genes
Unlike RAG1/2, which is a sequence specific endonuclease, 
AID can deaminate cytosines in nearly any sequence context, 
but it has a preference for RGYW motifs (Di Noia and Neu-
berger, 2007; Peled et al., 2008). This is a key feature of AID 
since mutations in a diverse collection of Ig variable regions 
maximizes the chances of producing somatic variants with 
higher affinity. An important question that remains to be 
answered is how AID finds its target genes and avoids produc-
ing widespread genomic damage.
An important first step in this direction lies in defining the set 
of genes that can be mutated by AID. Experiments with human 
and mouse B cells show that, in addition to Ig, AID can also 
mutate a number of oncogenes, including c-myc, Pim1, Pax5, 
and RHOH, as well as Bcl6, Igα, Igβ, and fas (Gordon et al., 2003; 
Müschen et al., 2000; Pasqualucci et al., 1998; Pasqualucci et 
al., 2001; Shen et al., 1998). Recently, a broad survey of 118 
genes expressed in germinal center B lymphocytes reveals that 
as many as 25% are mutated by AID, although most of these are 
hit at a frequency that is 100-fold lower than Ig (Liu et al., 2008). 
Interestingly, mutations at c-myc, the most frequent transloca-
tion partner for IgH in Burkitt’s lymphoma, are detected at close 
to background levels under physiological conditions (Liu et al., 
2008; Pasqualucci et al., 2001). However, c-myc accumulates 
AID-mediated mutations in the absence of base excision and 
mismatch repair pathways, indicating that some genes that are 
targeted by AID may be repaired in an error-free manner by the 
base excision and mismatch-repair machinery (Liu et al., 2008). 
Consistent with this notion and in contrast to IgH, c-myc does 
not show DSB repair foci in AID-expressing B cells under physi-
ological conditions (Robbiani et al., 2008).
Although the full extent of genomic damage produced by 
AID has not yet been defined, deregulated expression of AID 
in B cells leads to chromatid breaks and translocations involv-
ing nearly every chromosome (Robbiani et al., 2009). Thus, 
AID can produce mutations in many genes other than antibody 
genes, some of which are rapidly fixed by error-free pathways; 
others, that are not repaired, can produce DSBs that destabi-
lize the B cell genome.
Translocations Initiated by AID
After the discovery that AID mutates Ig variable and switch 
regions, it became possible to address the longstanding issue 
of the origin of DNA breaks in Ig switch regions that lead to 
oncogenic chromosomal translocations. Given that lesion 
formation at the IgH locus is codependent on AID and uracil 
DNA glycosylase, it could be predicted that these enzymes 
might also be required for chromosomal translocations asso-
ciated with class switching. This hypothesis is borne out by 
experiments demonstrating that AID is required for c-myc/IgH 
translocations, which are associated with IL-6 induced mouse 
plasmacytocis (Ramiro et al., 2004) and pristaine oil injections 
(Takizawa et al., 2008). Moreover, translocation is dependent 
on uracil DNA glycosylase (Ramiro et al., 2006), which indi-
cates that processing of U:G mismatches generated by AID is 
required for translocation (Ramiro et al., 2006).
AID is indirectly implicated in the pathogenesis of human 
lymphomas because it is expressed in some forms of lym-
phoma, including diffuse large B cell lymphoma (DLBCL), which 
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are characterized by IgH-associated chromosomal rearrange-
ments (Lenz et al., 2007). Direct evidence that deregulated 
AID expression leads to B cell lymphoma has only recently 
been obtained (Robbiani et al., 2009). Several groups pro-
duced transgenic mice expressing AID, beginning with Honjo 
and his colleagues (Okazaki et al., 2003). Some, but not all, of 
these mice are cancer prone, developing T lymphomas and 
epithelial tumors that are associated with aberrant SHM (Muto 
et al., 2006; Okazaki et al., 2003; Shen et al., 2008). However, 
although AID is almost exclusively expressed in B cells under 
physiologic circumstances, B cell lymphomas are not found in 
AID transgenic mice, even when the transgene is expressed 
exclusively in B cells (Muto et al., 2006). In addition, there are 
no chromosomal translocations in the tumors that eventually 
formed in non-B cells (Okazaki et al., 2003). Instead, cancers 
caused by the deregulated expression of AID are characterized 
by point mutations in oncogenes, as well as passenger muta-
tions in other nontumor-promoting genes (Okazaki et al., 2003). 
This apparent discrepancy between the absence of B cell lym-
phoma generation in vivo and frequent AID-mediated c-myc/
IgH translocation in vitro has been resolved by the discovery 
that AID deregulation leads to the rapid onset of mature B cell 
lymphoma when combined with deletion of p53 (Robbiani et 
al., 2009). In AID transgenic/p53-deficient mice, lymphomas 
almost invariably carry reciprocal clonal chromosome trans-
locations. Some of these translocations involve c-myc and 
IgH, reminiscent of Burkitt’s lymphoma, whereas others joined 
c-myc to the promoter of microRNA-142 (miR-142), a translo-
cation that is also found in human B cell leukemia (Gauwerky 
et al., 1989). Translocation between c-myc and miR-142 brings 
c-myc under the control of the mir-142 promoter and dereg-
ulates c-myc expression (Robbiani et al., 2009). miR-142 is 
likely to be involved in these cancer-producing translocations 
because it too is an AID target gene (Robbiani et al., 2009).
AID-Mediated DSBs in Non-Ig Genes
Relative to the amount of information we have about AID-medi-
ated DSBs at Ig loci, much less is known regarding the role of 
AID in producing DSBs in non-Ig genes. DSBs are detectable at 
the IgH, as evidenced by the focal accumulation of proteins that 
mark sites of DSBs (Petersen et al., 2001) (Figure 4, see below). 
However, these lesions cannot be detected at other loci such as 
c-myc despite strong evidence that AID produces DSBs in this 
gene (Robbiani et al., 2008). Genetic experiments that use the 
restriction enzyme I-Sce1 to create breaks in IgH, c-myc, or both 
in the presence or absence of AID show that AID is required to 
produce the DSBs at both loci. However, AID-generated breaks 
at IgH are more frequent than at c-myc, and the DSBs in c-myc 
are limiting for translocation (Robbiani et al., 2008; Wang et al., 
2009). Which other non-Ig genes besides c-myc are susceptible 
to AID-mediated DSB formation and how this compares to the 
degree to which these genes are somatically mutated has yet 
to be determined. An indication that DSBs and mutation in non-
Ig genes are correlated comes from the recent finding that Igβ, 
which is a known target for hypermutation by AID, is also a sub-
strate for translocation to IgH in stimulated B cells (Jankovic et 
al., 2010). Finally, deregulated expression of AID leads to chro-
matid breaks and translocations involving nearly every chromo-
some, which suggests that AID can produce DNA breaks in a 
diverse group of genes throughout the genome (Robbiani et al., 
2009). Thus, it is likely that many genes somatically mutated by 
AID also harbor DNA breaks that can serve as substrates for 
chromosome translocation.
Combined Action of RAG1/2 and AID
RAG1/2 and AID are usually expressed in distinct B cell devel-
opmental compartments. High levels of RAG1/2 are found in 
developing B cells in the bone marrow, whereas AID expres-
sion is found in mature B cells responding to antigen in the 
periphery. Assuming that DSBs are rapidly repaired, RAG1/2-
induced breaks and AID breaks should not coexist; therefore, 
Figure 4. Evolution of a DNA Repair Focus
A focus represents large-scale accumulation of factors in the chromatin flank-
ing a double-strand break (DSB). MRN recognizes the DSBs and recruits and 
activates ATM, a kinase that phosphorylates numerous factors at DSBs, in-
cluding histone H2AX and MDC1. Two E3 ubiquitin ligases, RNF8 and RNF168 
(coupled with the E2 enzyme UBC13), promote local chromatin ubiquitination, 
including ubiquitination of H2A histones. RNF8 and RNF168 promote chro-
matin retention of 53BP1 and Brca1. Modifications of histones may allow ex-
posure of partially occluded histone methyl marks, which facilitates retention 
of 53BP1. The complex of Rap80/Brca1 interacts directly with ubiquitinated 
histones. Foci formation stabilizes complexes on chromatin but is not required 
for their initial recruitment to damaged sites (Celeste et al., 2002).
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they should not be joined in chromosome translocations. 
However, RAG-induced DSBs can persist, especially in the 
absence of the ataxia telangiectasia mutated kinase (ATM), an 
essential DNA damage checkpoint regulator that prevents the 
long-term persistence of DSBs (Callén et al., 2009a; Callén et 
al., 2007). Cells that escape this checkpoint can have a DSB at 
the IgH locus even after RAG expression is extinguished and 
therefore these lesions could be paired with DSBs created by 
AID (Callén et al., 2007).
A second mechanism that facilitates translocation between 
RAG1/2 and AID breaks is the loss of the nonhomologous 
end-joining factor XRCC4 (Wang et al., 2009). Conditional 
deletion of this core component of the nonhomologous end-
joining machinery in mature B cells deficient in p53 leads to B 
cell lymphomas that carry tumor promoting c-myc/IgH trans-
locations, as well as translocations between the Igλ variable 
regions and IgH switch regions (Wang et al., 2008). These Igλ-
IgH passenger translocations appear to be the result of sec-
ondary V(D)J recombination (Wang et al., 2009), also known as 
receptor editing (Jankovic et al., 2004). This reaction appears 
to be mediated by delayed extinction of RAG1/2 expression, 
although the possibility of RAG reinduction cannot be ruled 
out definitively (Jankovic et al., 2004). The abnormal or delayed 
repair of RAG1/2-mediated DSBs in XRCC4 deficient cells, or 
potentially more rarely in normal cells, might promote overlap 
between the lesions created by the two Ig recombinases; this 
in turn could produce B cells in which both RAG1/2 and AID 
breaks coexist (Wang et al., 2008; Wang et al., 2009).
Finally, an analysis of an extensive panel of human chromo-
some translocations suggests that AID might facilitate off-tar-
get DSB formation by RAG1/2. According to this model, the 
low level AID expression in developing B cells in the bone mar-
row would create U:G mismatches that lead to the formation 
of non-B-DNA targets for RAG1/2, in genes like Bcl-2 (Tsai et 
al., 2008).
In conclusion, both RAG1/2 and AID can produce DSBs in 
Ig and non-Ig genes. The majority of RAG1/2 breaks are usu-
ally found in developing B cells, whereas the AID breaks are 
usually found in mature activated B cells. However, a number 
of mechanisms can facilitate the overlap between the two and 
thus might account for translocations between RAG1/2- and 
AID-mediated DSBs.
Repair Pathways in Aberrant Chromosome Joining
Nonhomologous End Joining and Homologous 
 Recombination
There are two well-described pathways that mediate DSB 
repair in mammalian cells: NHEJ and homologous recombina-
tion (HR) (Figure 3).
NHEJ directly relegates broken DNA, which can result in the 
loss of genetic material (Weinstock et al., 2006). Although this 
type of end joining can be active in any phase of the cell cycle 
and can compete with HR, it is essential for DSB repair in G0/
G1; therefore, it plays a major role in V(D)J recombination, class 
switching, and antigen receptor diversification-associated 
chromosome translocations (Chaudhuri et al., 2007; Jankovic 
et al., 2007). The absence of any of the core NHEJ compo-
nents leads to severe combined immunodeficiency, because of 
the inability to properly repair RAG breaks (de Villartay, 2009; 
Sleckman, 2005). Most of the core NHEJ factors (Ku70/80, 
XRCC4, Lig4) are also required for the efficient repair of AID 
breaks during class switching (Chaudhuri et al., 2007; Jankovic 
et al., 2007). However, the requirement for core NHEJ factors in 
switching is not absolute, and alternative end-joining pathways 
(A-NHEJ) that function in the absence of Ku70/80, Lig4, and 
XRCC4 (Figure 3) can mediate CSR at rates of up to 50% of 
normal (Boboila et al., 2010a, 2010b; Pan-Hammarström et al., 
2005; Soulas-Sprauel et al., 2007; Yan et al., 2007).
In contrast to NHEJ, repair of DSBs by HR utilizes the intact 
homologous chromatid as a complementary template; there-
fore, HR occurs primarily in S/G2/M (Figure 3). HR requires 
DSB resection to produce ssDNA substrates for homology 
search. Specifically, DNA ends must undergo 5′-3′ resection to 
generate 3′ ssDNA that recruits the RAD51 recombinase which 
mediates homologous pairing and strand invasion (Takeda et 
al., 2007) (Figure 3). DSB processing to ssDNA requires the 
formation of a complex that includes BRCA11, the MRN com-
plex (Mre11/Rad50/Nbs1), and CtIP (Chen et al., 2008; Sartori 
et al., 2007; Yun and Hiom, 2009), as well as Blooms Helicase 
and Exo1 (Gravel et al., 2008). In this context, Mre11 functions 
as a nuclease that is required for both DSB resection and HR 
(Buis et al., 2008; Paull and Gellert, 1998; Sartori et al., 2007). 
Finally, although DSB resection is essential for HR in the S/G2 
phase of the cell cycle, DSB resection also occurs in G0/G1 
(Yun and Hiom, 2009), where it may facilitate microhomology 
based alternative end joining (A-NHEJ) during class switch-
ing (A. Bothmer, D.F. Robbiani, N. Feldhahn, A.N., and M.C.N., 
unpublished data) and chromosome translocation (Simsek and 
Jasin, 2010).
HR in Translocation
Both NHEJ and HR are likely to play important roles in chromo-
some translocation (Weinstock et al., 2006). Consistent with 
this notion, there are several rare “chromosomal breakage” 
diseases that predispose to chromosomal translocation and 
cancer. Each of the genes mutated in these diseases encode 
proteins involved in DNA DSB repair. For example, Fanconi 
anemia, which is associated with bone marrow failure, blood, 
and solid tumors, is caused by mutations in one of 13 comple-
mentation groups, FANC A–N, some of which are implicated 
in HR (Moldovan and D’Andrea, 2009); Nijmegen breakage 
syndrome and ataxia telangiectasia, which are associated with 
an increased risk of lymphoma, arise from mutation in Nbs1 
and ATM respectively, both of which function in NHEJ and HR 
(Shiloh, 2003); and inherited breast cancer is frequently associ-
ated with mutations in BRCA1 or BRCA2, both of which func-
tion in HR (Venkitaraman, 2002).
In the absence of HR, cells experience an increase in general 
genomic instability (Sonoda et al., 1998) and a specific increase 
in the frequency of breaks at so-called fragile sites, which are 
large genomic regions prone to damage during replication stress 
(Arlt et al., 2006). In addition to DNA breakage, loss of BRCA1, 
BRCA2, BLM, or other HR proteins leads to the accumulation 
of radial and quasiradial structures, in which sister chromatids 
from different (homologous or nonhomologous) chromosomes 
fuse together (Venkitaraman, 2002). If the resulting radial type 
structure contains more than one centromere, then dicentric 
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chromosome rupture during mitosis could result in breakage-
bridge fusion cycles that may eventually lead to the propagation 
of a “stable” chromosomal translocation. Chromatid breaks that 
accumulate in Brca1-deficient cells are aberrantly joined by a 
Lig4 dependent mechanism, leading to the formation of radial 
structures (Bunting et al., 2010).
NHEJ and Translocation
Although classical NHEJ (C-NHEJ) core proteins are essential 
for intrachromosomal joining during V(D)J recombination and 
play an important role in class switching, their role in transloca-
tions appears to lie in suppressing rather than mediating these 
aberrant joining events. As was first shown in fibroblasts, loss 
of Ku80 and Lig4 leads to a massive increase in the frequency 
of spontaneous DNA breaks and chromosomal translocations 
(Difilippantonio et al., 2000; Ferguson et al., 2000; Karan-
jawala et al., 1999). Consistent with these results, transloca-
tions induced by RAG1/2, I-Sce1, or AID do not require Ku70, 
Ku80, DNA-PKcs, or XRCC4 (Boboila et al., 2010b; Callén et 
al., 2009b; Ramiro et al., 2006; Wang et al., 2009; Weinstock 
et al., 2007). On the contrary, the absence of Ku, XRCC4, 
Lig4, Artemis, or DNA-PKcs leads to the accumulation of AID-
dependent DNA breaks and translocations in stimulated B 
cells (Boboila et al., 2010b; Franco et al., 2008; Yan et al., 2007). 
The absence of C-NHEJ factors may promote abnormal join-
ing by increasing the number of DSB translocation substrates 
as a result of inefficient repair in cis, making it more probable 
that microhomology based A-NHEJ pathways fuse the ends 
together (see below).
A-NHEJ pathways are implicated in chromosomal translo-
cations on the basis of microhomology at the translocation 
breakpoints of some human cancers including nonlymphoid 
cancers (Weinstock et al., 2006). In mice, A-NHEJ is thought 
to mediate fusion-bridge-fusion translocations arising in B cell 
lymphomas in C-NHEJ/p53 double-deficient mice because 
the translocation junctions show microhomology (Difilippanto-
nio et al., 2002; Zhu et al., 2002). In addition, reciprocal chro-
mosome translocations between c-myc and IgH are C-NHEJ 
independent (Boboila et al., 2010b; Ramiro et al., 2006; Yan et 
al., 2007). Thus, A-NHEJ appears to be particularly active in 
chromosome translocations.
The A-NHEJ pathway was first described in mammalian cells 
by Roth and Wilson (Roth and Wilson, 1986). Although work 
from a number of laboratories and in different systems indi-
cates that this is a robust pathway (Boboila et al., 2010a; Pan-
Hammarström et al., 2005; Soulas-Sprauel et al., 2007; Yan et 
al., 2007), very little is known about the molecular components 
that mediate A-NHEJ. A-NHEJ appears to be conserved in 
yeast (McVey and Lee, 2008), may be kinetically slower than 
classical NHEJ (Boboila et al., 2010a; Han and Yu, 2008; Xie 
et al., 2009), and is biased toward microhomology mediated 
joins (typically 5–25 bp homologous sequences at the DSB 
junctions) (Haber, 2008; Zha et al., 2009). In contrast, classical 
NHEJ pathways anneal blunt ends or short (<4 bp) homologous 
sequences (Haber, 2008; Zha et al., 2009).
Among the repair factors implicated in A-NHEJ are Mre11 
and CtIP, which form a complex that regulates the initial DNA 
end resection at breaks, thereby exposing homologous ssDNA 
sequences for annealing (Bennardo et al., 2008; Deriano et 
al., 2009; Dinkelmann et al., 2009; Rass et al., 2009; Sartori 
et al., 2007; Xie et al., 2009; Yun and Hiom, 2009) (Figure 3). 
Loss of Mre11 decreases the joining efficiency between two 
I-SceI DSBs (Rass et al., 2009), and overexpression increases 
end resection and A-NHEJ, suggesting a role for Mre11 in DNA 
end resection and alternative end joining. Interestingly, another 
member of the complex that is essential for resection, BRCA1, 
is required for HR but is dispensable for A-NHEJ (Yun and 
Hiom, 2009). Other repair factors that may function in A-NHEJ 
and also as backup repair factors to C-NHEJ include the sin-
gle-strand break repair proteins DNA Ligase III (Lig3), XRCC1, 
and Poly (ADP-Ribose) Polymerase I (PARPI) (Robert et al., 
2009; Wang et al., 2006) (Figure 3). These proteins normally 
function in ssDNA repair, but might also act upon processed 
DSBs during A-NHEJ (Haber, 2008; Zha et al., 2009).
Alternative end joining may also mediate chromosomal 
fusions that occur in response to telomere erosion (Palm and de 
Lange, 2008). Loss of telomeric sequences results in the failure 
of DNA end protection, and chromosomal end fusions ensue. 
Like translocation, fusion of short telomeres occurs indepen-
dently of the end joining factors DNA-PKcs, ATM, and Lig4 
(Maser et al., 2007; Wong et al., 2003). In fission yeast, chro-
mosomal fusions induced by telomere attrition are also inde-
pendent of NHEJ but require the homologous recombination 
proteins Rad52 and ERCC1, which participate in single-strand 
annealing (Wang and Baumann, 2008). Single-strand anneal-
ing is a conserved pathway that repairs DSBs arising between 
long (>30 nt) flanking direct repeats via a mechanism involving 
annealing of the homologous ssDNA sequences. Single-strand 
annealing requires DSB processing and is dependent on Brca1 
and CtIP (Bennardo et al., 2008; Stark et al., 2004). In summary, 
the repair pathways involved in translocation are unknown, but 
they may involve single-strand DNA formation.
Although A-NHEJ is utilized when C-NHEJ is compromised, 
the extent to which it is active under physiological conditions 
and how the choice is made between the two pathways remains 
unclear. For example, a recent study analyzed the junctions of 
c-myc/IgH translocations produced in wild-type B cells (Rob-
biani et al., 2008). Half of the translocation junctions are blunt, 
and the other half show only 1–3 bp homology, which would be 
consistent with the known properties of C-NHEJ (Robbiani et 
al., 2008). This distribution and lack of extensive microhomol-
ogy is similar to junctions formed during normal class-switch 
recombination (Yan et al., 2007). This contrasts with transloca-
tion breakpoints found in the absence of C-NHEJ or by I-Sce1-
induced DSBs in AID-deficient B cells (Robbiani et al., 2008) 
or embryonic stem cells (Weinstock et al., 2007), which involve 
more extensive processing and microhomology-mediated join-
ing. End processing is inhibited by 53BP1. Loss of this factor 
promotes HR (Bunting et al., 2010) and microhomology-medi-
ated joining (A. Bothmer, D. F. Robbiani, N. Feldhahn, A.N., and 
M.C.N., unpublished data) and greatly alleviates replication 
associated genetic instability in Brca1-deficient cells (Bunting 
et al., 2010).
Focus-Forming Factors
Several DNA damage response proteins, such as Nbs1, ATM, and 
53BP1, accumulate in the chromatin region surrounding a DSB, 
forming what are called DNA damage repair “foci” (Fernandez-
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Capetillo et al., 2003) (Figure 4). Others, like the classical NHEJ 
proteins, seem to bind directly to DSBs but do not accumulate 
in regions distal to the break sites (Bekker-Jensen et al., 2006). 
For example, foci-forming proteins Nbs1, phosphorylated his-
tone H2AX (γ-H2AX), and 53BP1 accumulate on the IgH locus 
in response to AID-mediated breaks during class switching 
(Petersen et al., 2001) and on antigen receptor genes undergoing 
RAG1/2 dependent V(D)J recombination in thymocytes (Chen et 
al., 2000; Savic et al., 2009). The ability of proteins to form foci is 
dependent on prior phosphorylation of histone H2AX (γ-H2AX) 
(Celeste et al., 2002), a chromatin mark that spreads over a region 
spanning thousands to millions of base pairs of DNA (Rogakou et 
al., 1998). γ-H2AX is believed to serve as an anchor for stabilizing 
the binding of other focus forming factors to chromatin (Bassing 
and Alt, 2004; Fernandez-Capetillo et al., 2003), including the 
recently discovered histone ubiquitin E3 ligase RNF8 (Figure 4).
In addition to accumulating in foci at sites of antigen recep-
tor gene recombination, Nbs1, γ-H2AX, ATM, RNF8, and 53BP1 
are also required for the efficient completion of normal class 
switch recombination (Jankovic et al., 2007; Ramachandran et al., 
2010) (M.A. Santos, M.S.Y. Huen, M. Jankovic, A.N., and M.C.N., 
unpublished data), and some of these factors also contribute 
to V(D)J recombination (Bassing et al., 2003; Bredemeyer et al., 
2006; Celeste et al., 2003; Difilippantonio et al., 2008; Helmink et 
al., 2009). However, their role in these reactions is not completely 
understood. For example, the loss of 53BP1 in B cells undergoing 
CSR reduces the frequency of long-range joining between differ-
ent switch regions; however, short-range intraswitch joints appear 
to be increased (Reina-San-Martin et al., 2007), in part because 
of increased resection (A. Bothmer, D.F. Robbiani, N. Feldhahn, 
A.N., and M.C.N., unpublished data) (Bunting et al., 2010), which 
facilitates microhomology mediated A-NHEJ between repetitive 
switch sequences. Similarly, 53BP1 appears to be essential for 
repairing a subset of V(D)J recombination-induced ends, spe-
cifically those separated by long distances (Difilippantonio et al., 
2008). RNF8 is required for 53BP1 foci formation, yet the CSR 
defect in RNF8 knockout mice is milder than that observed in the 
absence of 53BP1 (Ramachandran et al., 2010) (M.A. Santos, 
M.S.Y. Huen, M. Jankovic, A.N., and M.C.N., unpublished data). 
Thus, in both CSR and V(D)J joining, loss of focus forming factors 
affects only a subset of joints and not end ligation per se. There 
are several models that could explain these phenomena, includ-
ing the possibility that 53BP1 stabilizes or promotes long-range 
chromosomal interactions (Difilippantonio et al., 2008), increases 
chromatin mobility (Dimitrova et al., 2008), or alters the repair 
pathway choice between C-NHEJ and A-NHEJ (A. Bothmer, D.F. 
Robbiani, N. Feldhahn, A.N., and M.C.N., unpublished data).
Many of the focus-forming factors are also essential to main-
taining genomic stability, and in their absence cells suffer an 
increase in chromosomal translocations. For example, the loss 
of either Nbs1, γ-H2AX, ATM, or 53BP1 leads to high levels 
of chromosomal aberrations during class switching, which are 
divided among general chromosomal aberrations and those 
occurring specifically at antigen receptor loci (Jankovic et al., 
2007). Furthermore, mutant mice that fail to express these fac-
tors are predisposed to cancer (Jankovic et al., 2007). Finally, 
the combined loss of ATM and DNA-PKcs leads to a synergis-
tic increase in genomic instability as well as additive defects in 
class switching, indicating that these proteins act redundantly 
in lymphocytes (Callén et al., 2009b). In summary, like NHEJ 
and HR proteins, focus-forming factors are not essential for 
interchromosome exchanges. On the contrary, their absence 
appears to result in aberrant or inefficient DSB repair in G0/G1, 
which may increase the availability of DSB substrates for trans-
location. In contrast, absence of 53BP1 reduces chromosomal 
instability in S phase and cancer predisposition in Brca1-defi-
cient cells (Bunting et al., 2010; Cao et al., 2009).
Translocation between c-myc and IgH
c-myc/IgH translocations belong to a special subset of trans-
locations that trigger oncogenic stress (Collado et al., 2007). 
Deregulated expression of oncogenes causes activation of the 
tumor suppressors ARF and ATM, which in turn trigger p53 
dependent senescence or cell death (Collado et al., 2007). 
This provides a barrier that protects cells against propagat-
ing the oncogenic translocation. Consistent with this notion, 
loss of Nbs1 (ATM activator), ATM, ARF, and p53 increases the 
frequency of c-myc/IgH but not Igβ/IgH translocations in pri-
mary B cells (Jankovic et al., 2010; Ramiro et al., 2006; Rob-
biani et al., 2009); mutations in ARF/p53 promote myc-induced 
lymphomagenesis (Eischen et al., 1999; Schmitt et al., 1999); 
deregulated AID expression causes cancer when p53 is dis-
rupted (Robbiani et al., 2009); and B cell lymphomas almost 
invariably carry mutations in these proteins in addition to trans-
locations (Küppers, 2005). Such secondary tumor-suppressor 
gene mutations may be necessary to avoid pathways that trig-
ger cell death; they appear to play a critical role in many tumors 
besides those of lymphoid origin (Halazonetis et al., 2008).
Interestingly, and in contrast to ATM, disruption of H2AX 
or 53BP1 does not affect the rate of c-myc/IgH translocation. 
However, their loss markedly increases IgH-associated translo-
cations to targets other than c-myc (Franco et al., 2006; Ramiro 
et al., 2006). One potential explanation for this paradox is that 
c-myc/IgH triggers an oncogenic stress signal that eliminates 
cells that carry this translocation, whereas Ig translocations to 
other regions may not be toxic. Support for this notion comes 
from the observation that the rate of translocation between 
IgH and Igβ (another AID target) is not altered by loss of p53 in 
the same cells that suffer increased c-myc/IgH translocations 
(Jankovic et al., 2010). Instead, alternative pathways that include 
BAFF, Bcl-XL, and PKC-δ protect cells against DNA damage in 
the absence of oncogenic stress (Jankovic et al., 2010).
In summary, the loss of either NHEJ or HR or focus-forming 
factors leads to an increase in the frequency of translocation and 
cancer predisposition. We speculate that the loss of these factors 
increases translocation because bona fide DSB repair is less effi-
cient, resulting in an increase in untethered ends that are available 
for intermingling, DSB processing and aberrant joining.
The Role of Nuclear Positioning in Translocation
In addition to being organized into nucleosomes, chromo-
somes are found in defined spatially segregated nuclear ter-
ritories that are in part correlated with transcriptional activity 
(Lieberman-Aiden et al., 2009). Physical proximity between 
translocated loci in the nucleus is an additional factor that may 
impact the frequency of translocation between chromosomes. 
For example, c-myc and IgH are frequently colocalized in pri-
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mary B cells but not in other cell types (Osborne et al., 2007; 
Wang et al., 2009). Importantly, this colocalization is found in 
resting B cells prior to AID-induced damage at c-myc and IgH, 
indicating that these loci are spatially proximal before DSBs 
are formed (Wang et al., 2009). The mechanisms that bring dis-
parate loci together in the nucleus are poorly understood; how-
ever, it has been proposed that loci that share transcriptional 
regulation are more likely to be found together (Spilianakis et 
al., 2005). However, accessibility for translocation does not 
appear to require transcription, given that even transcription-
ally silent c-myc is in an accessible nuclear compartment that 
permits c-myc/IgH translocation (Robbiani et al., 2008).
Quantitative high-resolution studies find that DSBs exhibit 
limited mobility similar to the random movement of undam-
aged chromatin (Kruhlak et al., 2006; Soutoglou et al., 2007). 
In contrast, a recent study of the dynamics of telomere fusions 
demonstrates that 53BP1 promotes end joining of dysfunc-
tional telomeres by increasing chromatin mobility (Dimitrova et 
al., 2008). They provide evidence that uncapped telomeres are 
more mobile and sample larger territories than normal telom-
eres in a manner dependent on 53BP1 (Dimitrova et al., 2008). 
The implication is that 53BP1 changes the dynamic behavior 
of chromatin to facilitate NHEJ reactions involving distant sites 
(Dimitrova et al., 2008). The potential role of 53BP1 or other fac-
tors in influencing chromatin dynamics, position, and translo-
cation is an important topic that is actively being investigated.
Conclusions
Paired DSBs are obligate intermediates for chromosomal 
translocation. Antigen receptor diversification reactions in 
lymphoid cells require the formation of DSBs that can serve 
as substrates for translocations. Importantly, the enzymes 
that produce DSBs in antigen receptor loci, RAG1/2 and AID, 
can also produce DNA lesions in nonantigen receptor genes, 
including oncogenes that can be paired with breaks in antigen 
receptor loci to form translocations.
Over the last decade, considerable progress has been made 
in understanding the way in which cells maintain genomic sta-
bility and avoid chromosomal translocations in the face of con-
tinual DNA damage produced during normal cellular metabo-
lism including antigen receptor gene recombination. Many 
of the factors that mediate DNA repair by HR and NHEJ also 
suppress translocation in normal cells. In the absence of these 
factors, mice and humans are prone to cancer-inducing chro-
mosomal translocations. An understanding of the mechanisms 
involved in the creation, signaling, and repair of DSBs will help 
target the activity of tumor-promoting oncogenes, as well as 
that of caretaker and gatekeeper genes whose loss contributes 
to tumor initiation and progression.
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